Last Patient Enrolled in the Phase 2 Trial with Transgene's TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC) - Associated Press

Last Patient Enrolled in the Phase 2 Trial with Transgene's TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)  Associated Press

Press release *content* from Business Wire. The AP news staff was not involved in its creation.